Richard Fisher
Chief Tech/Sci/R&D Officer bij Proclara Biosciences, Inc.
Profiel
Richard Fisher is currently the Chief Scientific Officer at Proclara Biosciences, Inc. He previously held positions as Director-Molecular Biology, Science & Technology at Biogen MA, Inc., Vice President-Research & Discovery at CytoMed, Inc., Senior VP-Research & Product Development at GlycoFi, Inc., and Vice President-Research & Discovery at UCB Research, Inc. He also served as the Chief Scientific Officer at Intranasal Therapeutics, Inc. Fisher received his undergraduate and doctorate degrees from the University of Iowa.
Actieve functies van Richard Fisher
Bedrijven | Functie | Begin |
---|---|---|
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01-01-2008 |
Eerdere bekende functies van Richard Fisher
Bedrijven | Functie | Einde |
---|---|---|
GlycoFi, Inc.
GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Chief Tech/Sci/R&D Officer | 01-01-2006 |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a private company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01-01-2005 |
CytoMed, Inc.
CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a private company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Chief Tech/Sci/R&D Officer | 02-01-1998 |
Intranasal Therapeutics, Inc. | Chief Tech/Sci/R&D Officer | - |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Richard Fisher
University of Iowa | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 6 |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Health Technology |
CytoMed, Inc.
CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a private company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Health Technology |
GlycoFi, Inc.
GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Health Technology |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a private company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Commercial Services |
Intranasal Therapeutics, Inc. |